An observational study in Chronic Renal Failure, sponsored by Vantive Health LLC. Completed at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Vantive Health LLC (formerly part of Baxter Healthcare Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Baxter Healthcare Corporation.
Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, this one is the only one that started in 2024, is one of 4 observational ones, and was the 33rd registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2024.
This study's enrollment of 439 is above the median of 120 across 445 observational studies indexed under Kidney Failure, Chronic.
Median enrollment 43 across the 29 interventional studies, 55 across the 4 observational. Of the 31 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Vantive Health LLC, one of the names counted as Baxter Healthcare Corporation. Under that name alone:
Vantive Health LLC is the lead sponsor of 55 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness and safety of icodextrin and glucose peritoneal dialysis (PD) solutions for the long dwell exchange in PD patients with continuous ambulatory peritoneal dialysis (CAPD), and to describe medical resource utilization in patients with PD on icodextrin.
Patients will be divided into icodextrin dialysate group (ICO group) and glucose dialysate group (glucose group).
ICO group: Patient data will be collected retrospectively and prospectively. Patients currently prescribed icodextrin will be recruited and enrolled. Data for these patients will included both retrospective historical data collection as well as a prospective collection of additional data. Within the relative look-back period (i.e., within 6 months before the launch of the study site), data will be collected from baseline (i.e., the most recent medical records prior to the first prescription of icodextrin) up to signing of the ICF. After providing informed consent, patient data will be prospectively collected for 12 months.
Additionally, any patients who are first prescribed icodextrin therapy after the launch of the study site will also be recruited and enrolled prospectively and data will be collected up to 12 months from enrollment for this group. For these patients, baseline will be defined as the most recent medical record from the time of signing the ICF to the first prescription of icodextrin.
Glucose group: Patient data will be collected retrospectively from CAPD patients followed up in the peritoneal dialysis center from July 1, 2018, to December 31, 2018. Retrospective data will be collected up to 12 months from baseline (i.e., the most recent peritoneal equilibration test date before December 31, 2018, in the peritoneal dialysis center).
The effectiveness and safety between the 2 groups will be analyzed.
Patients in China prescribed icodextrin or glucose PD solutions for continuous ambulatory peritoneal dialysis.
Inclusion Criteria for patients enrolled retrospectively in the ICO Group:
Inclusion Criteria for patients enrolled prospectively in the ICO Group:
Exclusion Criteria for the ICO Group:
Inclusion Criteria for the Glucose Group:
Exclusion Criteria for the Glucose Group:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Icodextrin is only intended for intraperitoneal administration and is recommended for long dwell during CAPD (i.e., recommended dwell time from 8-16 hours). Administration will be done at a rate that is comfortable for the patient, typically within 10-20 minutes.
Drug: Icodextrin Peritoneal Dialysis Solution
During CAPD, 2L of dialysis fluid is instilled into the peritoneal cavity and allowed to dwell for a certain period. The dwell time typically ranges from 4 to 8 hours during the day and 8 to 12 hours at night. This process is repeated 3 to 4 times a day, for 6 to 7 days a week. The frequency of solution exchanges may vary for each individual to achieve desired biochemical and solution control. Most solution exchanges utilize a 1.5% or 2.5% glucose dialysis solution. If more solution removal is required, a 4.25% glucose peritoneal dialysis solution can be used. Regular measurement of the patient's weight can be used to guide the setting of ultrafiltration volume.
Drug: Glucose Peritoneal Dialysis Solution
The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.
Also known as: Extraneal
The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
Comparison of the incidence of a composite endpoint for technique failure and death
Technique failure is defined as: * Treatment transferred from PD to HD/PHD \> 30 days; or * PHD, defined as adding HD treatment at least once every 2 weeks in 30 days during PD and requiring long-term combined HD as determined by the investigator. Death is specified as deaths during PD or deaths within 30 days with treatment from PD to HD/PHD
Time frame: 12 months
Comparison of the proportion of patients with technique failure
Number and proportion of patients with technique failure
Time frame: 12 months
Comparison of the incidence of cardiovascular events
Cardiovascular events include acute myocardial infarction, sudden severe arrhythmia ( a trial fibrillation and arrhythmia requiring hospitalization or medication), hospitalization for heart failure, stroke, and cardiovascular death.
Time frame: 12 months
Comparison of the incidence of the changes in ejection fraction
Change of the echocardiographic values from baseline: left ventricular ejection fraction fraction (LVEF)
Time frame: 12 months
Comparison of all-cause deaths
All-cause deaths refer to the total number of deaths from any cause within the study timeframe
Time frame: 12 months
Comparison of medical resource utilization in terms of hospitalizations
Excluding hospitalizations due to medicare payments or other non-medical issues. For ICO group only
Time frame: 12 months
Comparison of annual exchange dosage of ICO
For ICO group only
Time frame: 12 months
Plan to share: Yes — The Sponsor is committed to sharing clinical trial data with external medical experts and scientific researchers in the interest of advancing public health. As such, the Sponsor will supply anonymized Individual Patient Datasets (IPD) and supporting documents (synopsis of clinical study reports, protocol and SAP).
Supporting information: Study protocol, Statistical analysis plan
Time frame: Upon approval of a legitimate research request.
Access criteria: Research requests will be reviewed by qualified medical and scientific experts within the company. If the Sponsor agrees to the release of clinical data for research purposes, the requestor will be required to sign a data sharing agreement (DSA) in order to ensure protection of patient confidentiality and any intellectual property rights of the Sponsor prior to the release of any data.
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Jan 2026, 18 months.
Of 151 observational studies under Kidney Failure, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.